LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Strona główna・Stock List・Minerva Neurosciences Inc

Minerva Neurosciences Inc

Closed

6.19 2.48

Buy Sell

Overview

Share price change

24h

Current

Min

6.14

Max

6.44

Key metrics
By Trading Economics
Income	-281M -284M
P/E Sector Avg	2.462 57.05
EPS	-0.36
Employees	7

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+14.01% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-20M 285M
Previous open	3.71
Previous close	6.19

Minerva Neurosciences Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

21 paź 2025, 15:58 UTC

Major Market Movers

Minerva Shares Soar on $200 Million Financing for Schizophrenia Drug Trial

Peer Comparison

Price change

Minerva Neurosciences Inc Forecast

Price Target

By TipRanks

14.01% upside

12 Months Forecast

Average 7 USD 14.01%

High 7 USD

Low 7 USD

Based on 1 Wall Street analysts offering 12 month price targets forMinerva Neurosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Minerva Neurosciences Inc - Dist in the past 3 months.

Financials

Selling and administration expenses

Pre-tax profit

Sales

Interest expense on debt

Operating profit

About Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.